...
首页> 外文期刊>Eurosurveillance >Standardised surveillance of Clostridium difficile infection in European acute care hospitals: a pilot study, 2013
【24h】

Standardised surveillance of Clostridium difficile infection in European acute care hospitals: a pilot study, 2013

机译:欧洲急性护理医院艰难梭菌感染的标准化监测:一项试点研究,2013年

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Clostridium difficile infection (CDI) remains poorly controlled in many European countries, of which several have not yet implemented national CDI surveillance. In 2013, experts from the European CDI Surveillance Network project and from the European Centre for Disease Prevention and Control developed a protocol with three options of CDI surveillance for acute care hospitals: a ‘minimal’ option (aggregated hospital data), a ‘light’ option (including patient data for CDI cases) and an ‘enhanced’ option (including microbiological data on the first 10 CDI episodes per hospital). A total of 37 hospitals in 14 European countries tested these options for a three-month period (between 13 May and 1 November 2013). All 37 hospitals successfully completed the minimal surveillance option (for 1,152 patients). Clinical data were submitted for 94% (1,078/1,152) of the patients in the light option; information on CDI origin and outcome was complete for 94% (1,016/1,078) and 98% (294/300) of the patients in the light and enhanced options, respectively. The workload of the options was 1.1, 2.0 and 3.0 person-days per 10,000 hospital discharges, respectively. Enhanced surveillance was tested and was successful in 32 of the hospitals, showing that C. difficile PCR ribotype 027 was predominant (30% (79/267)). This study showed that standardised multicountry surveillance, with the option of integrating clinical and molecular data, is a feasible strategy for monitoring CDI in Europe.
机译:在许多欧洲国家,艰难梭菌感染(CDI)的控制仍然很差,其中一些国家尚未实施国家CDI监测。 2013年,来自欧洲CDI监控网络项目和欧洲疾病预防与控制中心的专家制定了一项协议,其中包括针对急诊医院的CDI监视的三种选择:“最小”选择(汇总医院数据),“简便”选项(包括CDI病例的患者数据)和“增强型”选项(包括每家医院前10次CDI发作的微生物学数据)。欧洲14个国家/地区的37家医院在三个月内(2013年5月13日至11月1日)测试了这些选择。所有37家医院都成功完成了最低限度的监测选择(针对1,152例患者)。 94%(1,078 / 1,152)轻度患者的临床数据已提交;在轻度和增强选项中,分别有94%(1,016 / 1,078)和98%(294/300)患者的CDI起源和结局信息完整。这些选项的工作量分别为每10,000例医院出院1.1、2.0和3.0人日。测试了增强的监控,并在32所医院中成功进行了测试,结果表明,艰难梭菌PCR核糖体027型占主导地位(30%(79/267))。这项研究表明,标准化的多国监测以及整合临床和分子数据的选择,是在欧洲监测CDI的可行策略。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号